CareLit · DOI-Nachweis · Diabetologie und Stoffwechsel
Evaluation of immunogenicity of LY2963016 insulin glargine compared with Lantus insulin glargine in patients with T1DM or T2DM
DOI 10.1055/s-0035-1549531
Bibliografische Angaben
Nachweis in CareLit
Autor:innenMA Deeg, L Ilag, WJ Huster, RK Pollom, JS Zielonka, M Prince, RJ Konrad
ZeitschriftDiabetologie und Stoffwechsel
Ausgabe04/2015
Jahrgang / SeitenNicht angegeben
Kernaussage aus der Literatur
Abstract-Vorschau
Introduction: The immunogenicity of LY2963016 (LY IGlar) and of Lantus® (IGlar), insulin glargine products with identical amino acid sequences, were compared, as subtle differences in protein products manufactured using living cells may affect the immune response and clinical outcomes. Methods: Anti-insulin glargine antibodies were measured in 52-wk and 24-wk studies in patients with T1DM (open-label) and T2DM (doub…
Zitieren
Zitierempfehlung
MA Deeg, L Ilag, WJ Huster, RK Pollom, JS Zielonka, M Prince, RJ Konrad (2015) Evaluation of immunogenicity of LY2963016 insulin glargine compared with Lantus insulin glargine in patients with T1DM or T2DM. Diabetologie und Stoffwechsel (04). https://doi.org/10.1055/s-0035-1549531
Mit CareLit weiterarbeiten